Shen Z, Mohiuddin M, Goldstein C, Yokoyama H, DiSesa V J
Department of Surgery, Medical College of Pennsylvania, Philadelphia 19129, USA.
J Thorac Cardiovasc Surg. 1996 Feb;111(2):429-31. doi: 10.1016/s0022-5223(96)70453-1.
Permanent acceptance of an experimental cardiac allograft can be achieved in the rat by pretreating the recipient with antilymphocyte serum and intrathymic donor lymphocytes. We investigated the durability and specificity of the tolerance produced by this pretreatment in a rat model of heterotopic heart transplantation with Lewis-Brown Norway donors and Lewis recipients. Pretreated Lewis rats received 1 ml antilymphocyte serum intraperitoneally and 5 x 10(7) Lewis-Brown Norway splenocytes intrathymically, followed 21 days later by Lewis-Brown Norway cardiac transplantation. The first Lewis-Brown Norway cardiac allograft survived long term (mean 140 days) in pretreated recipients who were given no subsequent immunosuppression. After 60 days with a beating Lewis-Brown Norway allograft, tolerant Lewis recipients underwent a second cardiac allograft with either a Lewis-Brown Norway heart or a third-party Wistar-Furth heart. The second Lewis-Brown Norway cardiac allograft was not rejected (mean survival 76 days), but that from the third-party Wistar-Furth donor was rejected in a normal fashion (mean survival 10.4 days). The presence of second grafts did not affect survival of first grafts. Tolerant Lewis recipients of two Lewis-Brown Norway heart grafts underwent subsequent transplantation with Lewis-Brown Norway skin. Skin allograft survival in this group (mean 8.4 days) was not different from that in Lewis recipients without pretreatment. Rejection of skin grafts had no effect on the heart grafts. These data suggest that tolerance to cardiac allografts produced by intrathymic pretreatment is durable and extends to a second heart graft from a genetically identical donor. Tolerant rats reject third-party hearts and primary donor skin grafts normally, and tolerance to previously placed heart grafts is not abrogated by this rejection. Non-major histocompatibility complex skin antigens not present on cardiac cells may account for the tissue specificity of the tolerance produced by intrathymic treatment in this model.
通过用抗淋巴细胞血清预处理受体并给予胸腺内供体淋巴细胞,可使大鼠对实验性心脏同种异体移植物产生永久性接受。我们在以Lewis-Brown Norway大鼠为供体、Lewis大鼠为受体的异位心脏移植大鼠模型中,研究了这种预处理所产生的耐受性的持久性和特异性。预处理的Lewis大鼠腹腔内注射1 ml抗淋巴细胞血清,胸腺内注射5×10⁷个Lewis-Brown Norway大鼠的脾细胞,21天后进行Lewis-Brown Norway大鼠心脏移植。首次Lewis-Brown Norway大鼠心脏同种异体移植物在未接受后续免疫抑制的预处理受体中长期存活(平均140天)。在有跳动的Lewis-Brown Norway大鼠同种异体心脏移植60天后,耐受的Lewis受体接受了第二次心脏移植,供体为Lewis-Brown Norway大鼠心脏或第三方Wistar-Furth大鼠心脏。第二次Lewis-Brown Norway大鼠心脏同种异体移植物未被排斥(平均存活76天),但来自第三方Wistar-Furth供体的移植物以正常方式被排斥(平均存活10.4天)。第二次移植物的存在不影响首次移植物的存活。接受两个Lewis-Brown Norway大鼠心脏移植物的耐受Lewis受体随后接受了Lewis-Brown Norway大鼠皮肤移植。该组皮肤同种异体移植物的存活时间(平均8.4天)与未预处理的Lewis受体无异。皮肤移植物的排斥对心脏移植物无影响。这些数据表明,胸腺内预处理产生的对心脏同种异体移植物的耐受性是持久的,并且扩展到来自基因相同供体的第二个心脏移植物。耐受的大鼠正常排斥第三方心脏和原供体皮肤移植物,对先前植入的心脏移植物的耐受性不会因这种排斥而被消除。在该模型中,心脏细胞上不存在的非主要组织相容性复合体皮肤抗原可能是胸腺内治疗产生的耐受性的组织特异性的原因。